Ishihara Sangyo Kaisha, Ltd.

The Green Cross Corporation

Research Association for Biotechnology of Agricultural Chemicals

Nobutoshi Yamada

Hideo Sugi

Takahiro Haga

Toru Koyanagi

Masahiro Watanabe

Tsunetaka Nakajima

Nobuo Kondo

Kazumasa Yokoyama

Hiroshi Okada

Kenji Kon

Masahiro Kikuchi

Keizo Miyata

Sadanori Mizukoshi

Yoshiyuki Aoyama

Hiroshi Shikama

Masanari Kato

Tadakazu Suyama

Hajime Murakami

Yoshimichi Ueda

Kenichi Ichimura

Hiroyuki Mori

Koichi Yamauchi

Tadao Okamoto

Taiji Katayama

Norifusa Matsuo

Takaaki Araki

Kouichi Yamauchi

Hideo Sugawa

Toru Mori

A polypeptide which is a tumor necrosis factor polypeptide having an amino acid sequence represented by from the 1st Ser to the 155th Leu as shown by SEQ ID NO:1 in the Sequence Listing, or its mutein, wherein the amino acid sequence of the 1st Ser to the 8th Asp of the SEQ ID NO:1 or the corresponding amino acid sequence of the mutein is replaced by an amino acid sequence containing at least one amino acid sequence of Arg-Gly-Asp and from 3 to 16 amino acids. Also disclosed are a recombinant plasmid containing a DNA encoding such a polypeptide, a recombinant microbial cell transformed by such a recombinant plasmid, a process for producing the polypeptide, a pharmaceutical composition comprising the polypeptide as an active ingredient, and a DNA for the polypeptide.

Muteins of TNF pharmaceutical compositions and a method of making

Peptide or its salt for autoimmune hyperthyroidism containing it

A polypeptide which is a tumor necrosis factor polypeptide having an amino acid sequence represented by from the 1st Ser to the 155th Leu as shown by SEQ ID NO:1 in the Sequence Listing, or its mutein, wherein the amino acid sequence of the 1st Ser to the 8th Asp of the SEQ ID NO:1 or the corresponding amino acid sequence of the mutein is replaced by an amino acid sequence containing at least one amino acid sequence of cell-adherent peptide of laminin and from 5 to 30 amino acids. Also disclosed are a recombinant plasmid containing a DNA encoding such a polypeptide, a recombinant microbial cell transformed by such a recombinant plasmid, a process for producing the polypeptide, a pharmaceutical composition comprising the polypeptide as an active ingredient, and a DNA for the polypeptide.

N-terminal muteins of tumor necrosis factor

Exo-3',4'-O-benzylidene-3'-dimethylchartreusin (exo-BDMC) or its salts and 3'-demethylchartreusin (3'-DMC) or its salts are provided according to the present invention. Exo-BDMC and its salts are useful for antitumorous agents and antibacterial agents. 3'-DMC and its salts are useful as starting materials for producing exo-BDMC.

Exo-3',4'-O-benzylidene-3'-demethylchartreusin and its salts

Antimicrobial powders are obtained by suppporting at least one antimicrobial metal of copper, zinc and alloys thereof on the surface of hydrous titanium oxide or titanium oxide particles by electroless plating, vapor deposition, compression mixing, mixing and reducing, and thermal decomposition of a compound. These powders are used to provide antimicrobial resin compositions, antimicrobial rubber compositions, antimicrobial glass compositions and antimicrobial coating compositions.

Method of making titanium oxide powder having antimicrobial metal

A polyhedrin gene of Spodoptera litura nuclear polyhedrosis virus (SlNPV C-411) has the following restriction enzyme cleavage map and about 3 kilobase pairs: ##STR1## At least a part of said polyhedrin gene can be substituted by a gene coding for a useful substance to construct a vector and a recombinant virus, and it is possible to produce a useful substance such as a peptide, protein or glycoprotein by culturing a cell infected with the recombinant virus.

Polyhedrin gene and genetic engineering thereof

A benzoyl urea compound-albumin complex comprising a benzoyl urea compound of the formula: ##STR1## wherein X is a halogen atom or a nitro group, Y is a hydrogen atom, a halogen atom, a nitro group or a trifluoromethyl group, Z.sub.1 is a halogen atom or a trifluoromethyl group, Z.sub.2 is a hydrogen atom or a halogen atom and A is CH or a nitrogen atom, and albumin.

Benzoyl urea compound-albumin complex

A substituted benzoylurea compound of the formula (I): ##STR1## wherein R.sup.1 is a hydrogen atom, a halogen atom or a nitro group, each of R.sup.2 and R.sup.3 is a hydrogen atom, an alkyl group, --COR.sup.6 (wherein R.sup.6 is an alkyl group or an alkoxy group) or --SO.sub.2 R.sup.6 (wherein R.sup.6 is as defined above), or R.sup.2 and R.sup.3 may form together with the adjacent nitrogen atom a heterocyclic ring, R.sup.4 is a halogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted alkylthio group or a nitro group, and R.sup.5 is a halogen atom, a nitro group or a substituted or unsubstituted alkyl group, or its salt.

Substituted benzoylurea compounds or their salts, processes for their

A powdery pharmaceutical composition comprising a benzoyl urea compound of the formula: ##STR1## wherein X is a halogen atom or a nitro group, Y is a hydrogen atom, a halogen atom, a nitro group or a trifluoromethyl group, Z.sub.1 is a halogen atom or a trifluoromethyl group, Z.sub.2 is a hydrogen atom or a halogen atom, and A is CH or a nitrogen atom, as an active ingredient, a nonionic surfactant as a dispersant, at least one member selected from the group consisting of sugar, sugar-alcohol and a nonionic surfactant as a disintegrant, and anhydrous silicic acid as a fluidizer.

Powdery pharmaceutical composition containing benzoyl urea, a dispersant

This invention relates to a novel chartreusin derivative of the general formula (I): ##STR1## and a salt thereof. This chartreusin derivative and a salt thereof have an excellent antitumor activity, which is exhibited even when the site of cancer inoculation and the site of drug administration are different. This invention further relates to an antitumorous composition containing the above-mentioned compound as active ingredient. This invention furthermore relates to a process for producing the above-mentioned chartreusin derivative or salt thereof.

Chartreusin derivatives and salts thereof

A pharmaceutical composition comprising a benzoyl urea compound having the formula: ##STR1## wherein X is a halogen atom or a nitro group, Y is a hydrogen atom, a halogen atom, a nitro group or a trifluoromethyl group, Z.sub.1 is a halogen atom or a trifluoromethyl group, Z.sub.2 is a hydrogen atom or a halogen atom, and A is a .dbd.CH--group or a nitrogen atom, and a nonionic surfactant.

Readily absorbed pharmaceutical composition

A substituted benzene derivative represented by a formula: ##STR1## where A represents: ##STR2## wherein X is a hydrogen atom, a halogen atom or a nitro group, R.sup.1 is --X.sup.1 Z.sup.1 (X.sup.1 is an oxygen atom or a sulfur atom and Z.sup.1 is a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group, a substituted or unsubstituted aryl group or a substituted or unsubstituted heteroaryl group), --COZ.sup.1 group (Z.sup.1 is as defined above), ##STR3## group (Z.sup.1 is as defined above, Z.sup.2 is --CO.sub.2 Z.sup.3 wherein Z.sup.3 is the same as Z.sup.1, or --SO.sub.2 Z.sup.3 wherein Z.sup.3 is as defined above and n is 0 or 1), ##STR4## (Z.sup.1 and Z.sup.3 are as defined above) or ##STR5## (X.sup.2, X.sup.3 and X.sup.4 are, respectively, an oxygen atom or a sulfur atom and Z.sup.4 and Z.sup.5 are the same as Z.sup.1), and R.sup.3 is a nitro group or ##STR6## (R.sup.4 and R.sup.5 are, respectively, an alkyl group, or they may form a heterocyclic group together with the adjacent nitrogen atom), or ##STR7## wherein X and R.sup.3 are as defined above and R.sup.2 is --X.sup.1 Z.sup.1 (X.sup.1 and Z.sup.1 are as defined above); Y is a halogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted alkylthio group, a nitro group or ##STR8## (R.sup.6 and R.sup.7 are, respectively, a substituted or unsubstituted alkyl group); R is ##STR9## (R.sup.8 is the same as Y and q is an integer of 1 to 4), ##STR10## (R.sup.8 is as defined above, and r is an integer of 1 to 3) or ##STR11## (R.sup.8 and r are defined above); and m is an integer, of 1 to 4, or its salt.

Substituted benzene derivatives, processes for their production and

A pharmaceutical composition comprising a benzoyl urea compound (A) selected from the group consisting of a benzoyl urea compound (I) having the formula: ##STR1## wherein X is a halogen atom, a nitro group or a trifluoromethyl group, provided that when Y is a nitro group, X is a halogen atom or a nitro group, Y is a hydrogen atom, a halogen atom, a nitro group or a trifluoromethyl group, Z.sub.1 is a halogen atom or a trifluoromethyl group, Z.sub.2 is a hydrogen atom or a halogen atom, and A is a .dbd.CH-- group or a nitrogen atom, and a benzoyl urea compound (II) having the formula: ##STR2## wherein each of X.sub.1 and X.sub.2 is a hydrogen atom, a halogen atom or a nitro group, provided that when Y is a nitro group, X.sub.1 is a hydrogen atom, Y is a hydrogen atom, a halogen atom, a nitro group or a trifluoromethyl group, and Z is a hydrogen atom, a halogen atom or a trifluoromethyl group, as an active ingredient; a nonionic surfactant as a dispersant; and at least one member selected from the group consisting of a saccharide, a saccharide alcohol, silicic anhydride and a nonionic surfactant, as a disintegrator.

Pharmaceutical composition

This invention relates to a novel chartreusin derivative of the general formula (I): ##STR1## and a salt thereof. This chartreusin derivative and a salt thereof have an excellent antitumor activity, which is exhibited even when the site of cancer inoculation and the site of drug administration are different. This invention further relates to a antitumorous composition containing the above-mentioned compound as active ingredient. This invention furthermore relates to a process for producing the above-mentioned chartreusin derivative or salt thereof.

A benzoyl urea compound having the formula: ##STR1## wherein X is a halogen atom, a nitro group or a trifluoromethyl group, provided that when Y is a nitro group, X is a halogen atom or a nitro group, Y is a hydrogen atom, a halogen atom, a nitro group or a trifluoromethyl group, Z.sub.1 is a halogen atom or a trifluoromethyl group, Z.sub.2 is a hydrogen atom or a halogen atom, and A is a .dbd.CH-- group or a nitrogen atom, or the formula: ##STR2## wherein each of X.sub.1 is X.sub.2 is a hydrogen atom, a halogen atom or a nitro group, provided that when Y is a nitro group, X.sub.1 is a hydrogen atom, Y is a hydrogen atom, a halogen atom, a nitro group or a trifluoromethyl group, and Z is a hydrogen atom, a halogen atom or a trifluoromethyl group, characterized in that its average particle size is not larger than 1 .mu.m.

Growing community of inventors

Kusatsu, Japan

Nobutoshi Yamada